Business
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and
About this update from Phibro Animal Health Corporation
[{"type":"text","content":"The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.\nJUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of protein based vaccines and therapeutics, and Phibro Animal Health (“Phibro”) (NASDAQ: PAHC), a leading global diversified animal health and mineral nutrition company, jointly announced that they have entered into an exclusive license agreement for a Phibro targeted disease. This agreement follows the successful proof of concept development work, including animal trials, which was previously completed by the two companies. Under the terms of the Agreement: Dyadic granted Phibro an exclusive license for its proprietary C1 -cell protein production platform to produce specific targeted antigens for development and commercialization of a poultry vaccine for a Phibro targeted disease.The parties will continue development work to find a vaccine candidate using Dyadic’s C1 cells.The parties expect to continue working on developing additional animal vaccine candidates to be produced from Dyadic’s C1-cells. “Phibro has been excellent to work with on this project and we look forward to expanding our collaboration to develop more cost-efficient, high-performance animal vaccines that can be produced from our proprietary and patented C1-cell protein production platform. Animal health continues to be a core market for Dyadic, where the broad utility of C1 engineered cell lines have the potential to significantly reshape how animal vaccines are brought to market and manufactured in terms of speed, scale, cost and manufacturing time,” said Mark Emalfarb, Dyadic's President and Chief Executive Officer. Avner Finger, Phibro’s Vice President of Research and Development commented, “Following the successful animal testing of antigens produced by Dyadic's C1 expression system for a targeted disease, we are pleased to be moving into the next stage of development to produce a viable vaccine...